Symptom Management in Patients on Dialysis

Sponsor
University Health Network, Toronto (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05515991
Collaborator
Humber River Hospital (Other)
30
2
2
9
15
1.7

Study Details

Study Description

Brief Summary

This is a parallel arm, pilot study used to examine the feasibility of electronic patient reported outcome measures (ePROMs) for symptom assessment and monitoring as well as a linked self-management support and decision support information hub (https://symptomcare.org) to facilitate symptom management for patients on maintenance hemodialysis.

Two dialysis centers will be included in the study, with one center receiving SUPPORT-Dialysis (intervention arm) and the other receiving standard care (control arm).

Condition or Disease Intervention/Treatment Phase
  • Other: SUPPORT-DIALYSIS with Access to Output Report and Information Hub
  • Other: SUPPORT-DIALYSIS Only
N/A

Detailed Description

In Canada, 20,000-25,000 patients with end-stage kidney disease (ESKD) experience a range of symptoms such as chronic pain, itchiness, fatigue, anxiety, depression and sleep disturbances [1-5]. These may impact quality of life, increase mortality, decrease treatment adherence, and increased hospitalizations [6-8]. These symptoms are under-managed and under-recognized among these patients, but screening and managing symptoms using patient reported outcomes measures (PROMs) may be a useful and inexpensive solution. PROMS have previously been used successfully in cancer care [8-9], and have potential for clinical care of patients with kidney failure as well.

Electronic collection of PROMs (ePROMs) facilitates PROMs use by allowing linkage to electronic patient records [10-11] and immediate scoring and presentation of results to patients and clinicians [12-14]. ePROMs allow the use of computer adaptive testing (CAT) to personalize questions, increase the precision of measurements and reduce survey burden [15-17]. The investigators also developed a self-management support and decision support resource hub(https://symptomcare.org) to help dialysis patients and their clinical team in identifying and managing relevant physical and psychological symptoms that require further assessment and potential intervention.

Patients will complete Patient Reported Outcome Measurement Information System (PROMIS) CAT surveys on an electronic data capture system (SUPPORT-Dialysis) every four weeks during their dialysis treatment for six months. In the intervention, patients with moderate/severe symptoms will be flagged for the clinical team. Moderate/severe symptoms will be determined based on whether the participants score above a pre-defined cut-off in the surveys. The participant, primary nurse, and nephrologist will also receive an output report and be given access to https://symptomcare.org for suggested symptom management actions.

To establish the feasibility and acceptability of the intervention, the investigators will assess

  1. Recruitment Rate

  2. Retention and Completion rate

  3. Acceptability

  4. Patient satisfaction

  5. Staff satisfaction

Based on the objectives of this study, the investigators hypothesize the following:
  1. Recruitment goals will be met; >50% of approached patients will consent; completion rate will be > 80% of participants at least 50% of the time, and dropout rate will be < 30%.

  2. 80% of patients find the toolkit acceptable; <20% of staff find the process intrusive to workflow.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Assessing the Feasibility of Self-reported MeasUrement of Physical and PsychosOcial Symptoms and Response Tool in Patients on Dialysis- Pilot Study
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: SUPPORT-DIALYSIS with Access to Output Report and Information Hub

Feasibility of SUPPORT-Dialysis at Toronto General Hospital

Other: SUPPORT-DIALYSIS with Access to Output Report and Information Hub
SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team. Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals.

Experimental: SUPPORT-DIALYSIS Only

Usual Treatment at Humber River Hospital

Other: SUPPORT-DIALYSIS Only
SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.

Outcome Measures

Primary Outcome Measures

  1. Recruitment Target [Baseline]

    Feasibility of toolkit will be confirmed if recruitment target of 30 participants at each site are obtained in a 3-month period of the pilot.

  2. Proportion of Eligible Patients who decline consent [Baseline]

    Feasibility of toolkit will be confirmed if decline rate is <50% for eligible patients.

  3. Proportion of Participants who miss or refuse ePROMs follow-ups [Baseline to follow-up (6 months)]

    Feasibility of toolkit will be confirmed if <30% of participants complete <50% of all follow-up visits.

  4. Proportion of Enrolled Patients who Drop-Out From the Study [Baseline to follow-up (6 months)]

    Feasibility of toolkit will be confirmed if the dropout rate is < 30%.

Secondary Outcome Measures

  1. Patient Acceptability [Follow-up (every 4 weeks, up to 6 months)]

    Proportion of patients who find the tool 1) acceptable, 2) not burdensome and 3) important, based on responses to the "Patient Satisfaction Survey" they will complete.

  2. Clinical Team Acceptability [Follow-up (every 4 weeks, up to 6 months)]

    Proportion of staff who do not find the use of the tool intrusive to the workflow, based on responses to the "Staff Satisfaction Survey" they will complete.

Other Outcome Measures

  1. Incidence Rate of Healthcare Use [Baseline to Follow-up (6 months)]

    Patients will complete the 'Healthcare Use Questionnaire' at each follow-up visit. Incidence rate of healthcare use will be determined via incidence of hospitalization and emergency visits every 4 weeks.

  2. Physical Health Component Score [Baseline to Follow-up (6 months)]

    Measured by the 36-Item Kidney Disease Quality of Life Instrument (KDQOL-36) and the 12-Item Short Form Health Survey (SF-12) embedded in ePROMs. SF-12 is a part of KDQOL-36, specifically items 1-12. Scoring wise, items 1, 8, & 12-36 have a minimum value of 1 and maximum value of 5. Items 2 & 3 have a minimum value of 1 and maximum value of 3. Items 4-7 have a minimum value of 1 and maximum value of 2. Items 9-11 have a minimum value of 1 and maximum value of 6. Whether higher or lower scores determine better outcomes depends on the item.

  3. Mental Health Component Score [Baseline to Follow-up (6 months)]

    Measured by the 36-Item Kidney Disease Quality of Life Instrument (KDQOL-36) and the 12-Item Short Form Health Survey (SF-12) embedded in ePROMs. SF-12 is a part of KDQOL-36, specifically items 1-12. Scoring wise, items 1, 8, & 12-36 have a minimum value of 1 and maximum value of 5. Items 2 & 3 have a minimum value of 1 and maximum value of 3. Items 4-7 have a minimum value of 1 and maximum value of 2. Items 9-11 have a minimum value of 1 and maximum value of 6. Whether higher or lower scores determine better outcomes depends on the item.

  4. Kidney Disease Quality of Life [Baseline to Follow-up (6 months)]

    Measured by the 36-Item Kidney Disease Quality of Life Instrument (KDQOL-36). Scoring wise, items 1, 8, & 12-36 have a minimum value of 1 and maximum value of 5. Items 2 & 3 have a minimum value of 1 and maximum value of 3. Items 4-7 have a minimum value of 1 and maximum value of 2. Items 9-11 have a minimum value of 1 and maximum value of 6. Whether higher or lower scores determine better outcomes depends on the item.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients undergoing maintenance hemodialysis for more than 3 months
Exclusion Criteria:
  • Patients with severe acute illness or condition that hampers questionnaire completion assessed by clinical team.

  • Dementia indicated in the medical record, indicated by the managing healthcare team.

  • Unable to understand English - as assessed by clinical team.

  • Life expectancy < 6 months as assessed by main responsible nephrologist.

  • Unwilling or unable to provide informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Humber River Hospital Brampton Ontario Canada M3M 0B2
2 Toronto General Hospital Toronto Ontario Canada M5G2C4

Sponsors and Collaborators

  • University Health Network, Toronto
  • Humber River Hospital

Investigators

  • Principal Investigator: Istvan Mucsi, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT05515991
Other Study ID Numbers:
  • 22-5199
  • UHNKHERGePROMSUPPORTDIALYSIS
First Posted:
Aug 25, 2022
Last Update Posted:
Aug 25, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Health Network, Toronto
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2022